TY - JOUR
T1 - Current drug use and lack of HIV virologic suppression
T2 - Point-of-care urine drug screen versus self-report
AU - Qian, Han Zhu
AU - Mitchell, Valerie J.
AU - Bebawy, Sally
AU - Cassell, Holly
AU - Perez, Gina
AU - McGowan, Catherine C.
AU - Sterling, Timothy R.
AU - Vermund, Sten H.
AU - D'Aquila, Richard
AU - Hulgan, Todd
N1 - Funding Information:
This study was supported by Vanderbilt-Meharry Center for AIDS Research Developmental Grant (NIH grant P30 AI 54999) and Vanderbilt Institute for Clinical and Translational Research grant support (1 UL1 RR024975). This project was conducted utilizing the services of the Survey Research Shared Resource at Vanderbilt Medical Center which is supported in whole or in part by the Cancer Center Supporting Grant # P30CA068485 funded by the National Cancer Institute. The funders had no role in study design, data collection, analysis, decision to publish or preparation of the manuscript.
Publisher Copyright:
© 2014 Qian et al.; licensee BioMed Central Ltd.
PY - 2014/9/18
Y1 - 2014/9/18
N2 - Background: There have been inconsistent findings on the association between current drug use and HIV disease progression and virologic suppression. Drug use was often measured using self-report of historical use. Objective measurement of current drug use is preferred.Methods: In this cross-sectional study, we assessed drug use through Computer-Assisted Self Interviews (CASI) and point-of-care urine drug screen (UDS) among 225 HIV-infected patients, and evaluated the association between current drug use and virologic suppression.Results: About half (54%) of participants had a positive UDS, with a lower self-reported rate by CASI (42%) (Kappa score = 0.59). By UDS, 36.0% were positive for marijuana, 25.8% for cocaine, 7.6% for opiates, and 2.2% for methamphetamine or amphetamine. Factors associated with virologic suppression (plasma HIV RNA <50 copies/mL) were Caucasian race (P = 0.03), higher CD4 count (P < 0.01), current use of antiretroviral therapy (ART) (P < 0.01), and a negative UDS (P < 0.01). Among 178 current ART users, a positive UDS remained significantly associated with lower likelihood of virologic suppression (P = 0.04).Conclusions: UDS had good agreement with CASI in detecting frequently used drugs such as marijuana and cocaine. UDS at routine clinic visits may provide " real-time" prognostic information to optimize management.
AB - Background: There have been inconsistent findings on the association between current drug use and HIV disease progression and virologic suppression. Drug use was often measured using self-report of historical use. Objective measurement of current drug use is preferred.Methods: In this cross-sectional study, we assessed drug use through Computer-Assisted Self Interviews (CASI) and point-of-care urine drug screen (UDS) among 225 HIV-infected patients, and evaluated the association between current drug use and virologic suppression.Results: About half (54%) of participants had a positive UDS, with a lower self-reported rate by CASI (42%) (Kappa score = 0.59). By UDS, 36.0% were positive for marijuana, 25.8% for cocaine, 7.6% for opiates, and 2.2% for methamphetamine or amphetamine. Factors associated with virologic suppression (plasma HIV RNA <50 copies/mL) were Caucasian race (P = 0.03), higher CD4 count (P < 0.01), current use of antiretroviral therapy (ART) (P < 0.01), and a negative UDS (P < 0.01). Among 178 current ART users, a positive UDS remained significantly associated with lower likelihood of virologic suppression (P = 0.04).Conclusions: UDS had good agreement with CASI in detecting frequently used drugs such as marijuana and cocaine. UDS at routine clinic visits may provide " real-time" prognostic information to optimize management.
KW - Antiretroviral therapy
KW - Computer-assisted self-interview
KW - Drug use
KW - HIV
KW - Urine drug screen
KW - Virologic suppression
UR - http://www.scopus.com/inward/record.url?scp=84908092968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908092968&partnerID=8YFLogxK
U2 - 10.1186/1471-2334-14-508
DO - 10.1186/1471-2334-14-508
M3 - Article
C2 - 25234368
AN - SCOPUS:84908092968
SN - 1471-2334
VL - 14
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
IS - 1
M1 - 508
ER -